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INTRODUCTION
The inflammatory nature of atherosclerosis and certain links
between infection and atherothrombosis have been de-
scribed by many researchers (Ross, 1973; Ross et al., 1976;
Ross, 1986; 1993a; 1993b).
Chronic infection could be one of the possible causative
factors involved as it causes dysfunction and inflammation
of endothelium (Libby et al., 1997). Infection agents and vi-
ruses damage and transform the vascular wall, thus directly
causing endothelium and smooth muscle cell dysfunction.
Indirect influence on both atherosclerosis and atherothrom-
bosis can occur by affecting leukocytes (including macro-
phages and lymphocytes, commonly found in atheromata)
in the following ways: decrease of fibrinolytic activity,
stimulation of procoagulant and cytotoxin production, and
atherogenic changes in lipid metabolism. Infectious agents
are essential for the immune system activation; it has been
shown that flu vaccinated individuals less frequently de-
velop acute vascular events, compared to unvaccinated peo-
ple (Nichol et al., 2003; Smeeth et al., 2004).
Cytomegalovirus (CMV), known as Human Herpesvirus
(HHV5), belongs to the beta Herpes virus subfamily (Mo-
carski et al., 2001) and is found in all geographic regions
and socioeconomic groups (Ryan et al., 2004). CMV infects
between 50% and 80% of the population, and its seropreva-
lence is age-dependent. CMV may affect any organ. As a
latent infection it persists in the organism over long periods,
and intermittently can be transmitted to the environment.
The virus is associated with the salivary glands. Develop-
ment of CMV is dependent on many factors: route of infec-
tion, genetic features of the host, as well as the immune sys-
tem status. CMV can be found in all bodily fluids — urine,
saliva, tears, sperm, and breast milk (Ho, 1990). Postnatally,
infection mainly affects the respiratory and digestive sys-
tems. In blood CMV mainly replicates in macrophages (leu-
kocytes and monocytes), or persists in the lymphoid tissues.
A CMV infected macrophage induces MCR-1 (monocyte
chemotactic protein) expression. Therefore, CMV can be
considered as a MCR-1 expression “mediator”, the mecha-
nism leading to endothelial damage (Stern et al., 2008).
Similar to Chlamydia pneumoniae, chronic CMV infection
is also associated with vascular smooth muscle cell prolifer-
ation (Epstein et al., 1999 ) and increase of carotid athero-
sclerosis and intima media thickness (Nieto et al., 1996).
Studies focused on CMV identification in atherosclerotic
plaques have showed ambiguous results, moreover, virus
antibody titres have not always correlated with clinical find-
ings (Chiu et al., 1997; Saetta et al., 2000). CMV diagnos-
tics are based on serologic and molecular methods.
The aim of our study was to compare the plasma Cytomega-
lovirus IgG antibody level in a stroke patient and control
groups and to determine association of homocysteine with
ischemic stroke and with stroke subtype.
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Stroke is the second most common cause of death in the world and a major cause of long-term
disability. Chronic infection is an independent risk factor for ischemic stroke and related forms of
atherosclerotic vascular disease. The aim of our study was to compare the plasma Cytomegalovi-
rus (CMV) immunoglobulin G antibody level in a patient and control group, and to determine the
association of CMV chronic infection with ischemic stroke, and with stroke subtype. The present
study does not present a cogent demonstration that cytomegalovirus chronic infection is a risk
factor of stroke. Further studies are necessary to clarify the effective prophylactic measures to de-
termine other significant risk factors for stroke.
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MATERIALS AND METHODS
This study was prospective and all patients (n = 102) in-
cluded in this study were hospitalised in Pauls Stradiòð
Clinical University Hospital in the Clinic of Neurology with
the diagnosis of acute ischemic stroke (61 males, 41 fe-
males; mean age 65.8 ± 10.9 years; age range 42 to 89
years). The control group included 48 people (26 males, 22
females; mean age: 64.3 ± 11.8 years; age range 42 to 82
years). Patients were divided into three groups according to
TOAST criteria: patients with atherotrombotic stroke sub-
type (n = 36), cardioembolic stroke subtype (n = 47) and
with undetermined aetiology subtype (n = 19). General
characteristics of the 102 cases in subgroups are presented
in Tables 1 and 2. The average age of patients in subgroups
significantly differed (F = 4.631; P < 0.05), which can be
explained by different pathogenesis and aetiology mecha-
nisms in the stroke subgroups.
The severity of neurological status of patients was clinically
evaluated using the Rankin scale. Special inquiry forms
were completed for each of patients with the following in-
formation: stroke localisation (ACM, ACA or VB territory),
and stroke risk factors (hypertension, diabetes, cigarette-
smoking, blood lipids and others).
Quantitative/qualitative determination of IgG antibodies to
Cytomegalovirus in plasma and sera (ADALTIS EIAgen
Cytomegalovirus IgG Kit) in plasma was conducted by
ELISA. The test had in vitro diagnostic use only. Micro-
plates are coated with native Cytomegalovirus antigen,
highly purified by sucrose gradient centrifugation and inac-
tivated. The solid phase was first treated with the diluted
sample and immunoglobulin G (IgG) to Cytomegalovirus
were captured, if present, by the antigens. After washing out
all of the components of the sample, in the 2nd incubation,
bound anti Cytomegalovirus Ig G were detected by the ad-
dition of polyclonal specific and hIgG antibodies, labelled
with peroxidase (HRP). The enzyme captured on the solid
phase, acting on the substrate/chromogen mixture, generates
an optical signal that is proportional to the amount of anti
CMV IgG antibodies present in the sample. A Calibration
Curve, calibrated as the 1st WHO international standard was
used for quantitative determination of the IgG antibody in
the patient. Samples with a concentration lower than 0.5
IU/ml are considered negative for anti Cytomegalovirus IgG
antibody. Samples with a concentration higher than 0.5
IU/ml were considered positive for anti-CMV IgG antibody.
Persons with blood samples whose anti-CMV IgG antibody
concentration was expected to be higher than 8 IU/ml in this
study were classified as patients who had massive contact
with virus.
SPSS 16 software was used for statistical data processing.
To test hypotheses in line with the set tasks and type of data
the parametric and non-parametric statistical methods were
used.
RESULTS
CMV IgG seropositivity was not associated with a particu-
lar case group. The prevalence of Ig G higher than 0.5
IU/ml did not differ between patient and control groups
(χ2 = 0.02; P > 0.05) (Table 3). Subgroup analyses show
similar negative results (Table 4).
The mean CMV IgG antibody level was not significantly
higher in the patient group (t = 1.274; P > 0.05) (Table 5).
There was no significant difference between mean level of
CMV antibody in different stroke subtypes (F = 3.27; P <
0.05) (Table 6).
The patient and control groups were divided into two sub-
groups — with IgG to CMV level from 0.5 IU/ml to 8
T a b l e 1
AVERAGE AGE IN PATIENT GROUPS
Patient
subgroup






Atherotrombotic 36 63.2 11. 3 59.4 67.02
Cardioembolic 47 69.9 8.8 67.4 72.51
Undetermined 19 60.7 11.9 54.9 66.44
T a b l e 2




Atherotrombotic 28 (77.8%) 8 (22.2%)
Cardioembolic 21 (44.6%) 26 (45.4%)
Undetermined 12 (63.2%) 7 (36.8%)
T a b l e 3
NUMBERS OF PATIENTS WITH CMV IgG HIGHER THAN 0.5 IU/ML






Patients with CMV IgG
higher than 0.5 IU/ml (n)
95 45 0.02
IgG, immunoglobulin G; * P > 0.05; CMV, Cytomegalovirus
T a b l e 4
THE PROPORTION (%) OF PATIENTS WITH CMV IgG HIGHER
THAN 0.5 IU/MIN IN GROUPS WITH DIFFERENT STROKE SUB-










Atherotrombotic 97 93 1.68
Cardioembolic 92 93 0.07
Underterminated 86 93 2.61
IgG, immunoglobulin G; * P > 0.05; CMV, Cytomegalovirus
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IU/ml and above 8 IU/ml (Table 7). The prevalence of
seropositivity to IgG (>8 IU/ml) antibodies was signifi-
cantly higher in cardioembolic stroke cases (75%) than in
controls (52%) (x = 5.11; P < 0.05). These results suggest
that associations between high concentration of anti CMV
IgG and atherosclerosis is mostly found in cardiovascular
patients.
We found a correlation between CMV IgG antibody level
and leucocitosis (r = 0.282; P < 0.05), coronary heart dis-
ease (r = 0.239; P < 0.05), and thickness of intima-media
complex (r = 0,221; P < 0.05), which might suggest CMV
seropositivity as a stimulator of chronic inflammation and
an independent predictor of atherosclerosis.
DISCUSSION
Our study does not provide an unambiguous answer on the
role of chronic infection in stroke etiology. Several prob-
lems should be solved in order to confirm the infection the-
ory. Chronic infection is widespread in the population, and
therefore, can not be considered as a specific risk factor. In
our study, CMV IgG seropositivity was detected in 93% of
the patient group and in 94% of the control group cases.
Cytomegalovirus chronic infection is an associate with pro-
liferation of vascular smooth-muscle cells (Epstein et al.,
2004) and increase thickness of intima-media complex
(Nieto et al., 1996). In our study, we also found a correla-
tion between CMV IgG antibody level and thickness of in-
tima-media complex (r = 0.221; P < 0.05). We can not also
exclude the importance of cytomegalovirus chronic infec-
tion combination with other risk factors, such as coronary
heart disease (Amarenco et al., 1994) and white blood cell
count (Grau et al., 2001). This study shows an association
between CMV IgG antibody level and leucocitosis (r =
0.282; P < 0.05) and coronary heart disease (r = 0.239; P <
0.05).
It still remains unclear whether chronic infection induces
the onset of atherosclerosis, or merely contributes to the
progression of the latter. In the search for clinical evidence
for the chronic infection theory, more verified associations
between microorganisms and atherosclerosis have been
mostly found in cardiovascular patients, where diversity of
risk factors have been excluded. This can be difficult to
achieve in stroke patients due to stroke heterogeneity.
Another important problem to solve is the methodology of
detection: the optimal method for detecting of the infectious
agents has not been accepted yet. The role played by mo-
lecular methods in a routine diagnostic virus laboratory is
still small compared to conventional methods. One of the
newer molecular techniques is the polymerase chain reac-
tion (PCR). PCR has many problems, mainly contamina-
tion, since only a minute amount of contamination is needed
to give a false positive result. In addition, because PCR is
so sensitive compared to other techniques, a positive PCR
result is often very difficult to interpret as it does not neces-
sarily indicate the presence of disease. This problem is par-
ticularly large in the case of latent viruses such as CMV,
since latent CMV genomes may be amplified from the
blood of healthy individuals. Serology forms the mainstay
of viral diagnosis, as it shows primary humoral immune re-
sponse to antigen. The ELISA method is relatively cheap,
sufficiently sensitive and more often is used as a routine
method in clinical practice.
The definition of chronic infection in perspective probably
can be recommended as a routine analysis, especially for
stroke patients with dyslipidemia, coronary heart disease,
T a b l e 5






Mean CMV IgG antibody level
( IU/ml )
6.43 ± 2.6 5.83 ± 2.7
CMV, Cytomegalovirus; IgG, immunoglobulin G; * P > 0.05
T a b l e 6
MEAN CMV IgG ANTIBODY LEVEL (IU/ML) IN DIFFERENT
STROKE SUBTYPES






Atherotrombotic stroke 36 6.392 2.4168 5.416 7.368
Underterminated stroke 19 5.019 3.4431 3.359 6.678
Cardioembolic stroke 47 7.022 2.0625 6.417 7.628
Control group 48 5.833 2.7181 5.044 6.623
Total 150 6.226 2.6389 5.785 6.667
CMV, Cytomegalovirus; IgG, immunoglobulin G
T a b l e 7










stroke (n = 19)
χ2;
P
Patient group/ control group with IgG
CMV < 8 IU/ml
14/23 0.96; 12/23 5.11; 7/23 0.68;
Patient group/ control group with IgG
CMV > 8 IU/ml
22/25 > 0.05 35/25 < 0.05 12/25 > 0.05
CMV, Cytomegalovirus; IgG, immunoglobulin G
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and stenotic changes in carotid vessels. It remains necessary
to continue studies to clarify the role of chronic infection in
the Latvian population. CMV detection in native tissue may
be the next step to the investigation of tropism of infection.
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CITOMEGALOVÎRUSS KÂ CEREBRÂLA INFARKTA RISKA FAKTORS: PROSPEKTÎVS PÇTÎJUMS
Citomegalovîruss (CMV) ir zinâms arî kâ cilvçka herpesvîruss 5 (HHV5), tas pieder pie beta herpesvîrusu dzimtas un ir sastopams visos
ìeogrâfiskajos reìionos un sociâlekonomiskajâs grupâs. Ar CMV inficçti 50–80% populâcijas un tâs seroprevalence tieði korelç ar vecumu.
Nonâkot asinîs, CMV reproducçjâs leikocîtos un monocitâto makrofâgu sistçmas ðûnâs vai persistç limfoîdos audos. Makrofâgs, kas ir
inficçts ar vîrusu, sâk stimulçt MCR-1 ekspresiju, lîdz ar to CMV var nosaukt par starpnieku MCR-1 ekspresijas procesâ – tas ir
mehânisms, kas veicina endotçlija bojâjumu. Hroniska CMV infekcija varçtu bût viens no iespçjamajiem iesaistîtajiem faktoriem, kas
izraisa endotçlija disfunkciju un iekaisumu, stimulçjot aterosklerozi. Mûsu pçtîjuma mçríis bija izpçtît citomegalovîrusa hronisko infekciju
kâ cerebrâla infarkta riska faktoru, tâ saistîbu ar insulta apakðtipu un citiem riska faktoriem. Pçtîjums veikts Paula Stradiòa Klîniskajâ
universitâtes slimnîcâ Neiroloìijas nodaïâ, un tajâ piedalîjâs 150 cilvçki. Pçtîjumâ pamata grupâ bija iesaistîti 102 pacienti, no tiem 61
vîrietis un 41 sieviete vecumâ no 42 lîdz 89 gadiem, vidçjais vecums 65,8 ± 10,9 gadi. Kontroles grupâ bija 48 cilvçki, no tiem 26 vîrieði un
22 sievietes vecumâ no 42 lîdz 82 gadiem, vidçjais vecums 64,3 ± 11,8 gadi. Pacientu grupai un kontroles grupai bija noteikts
imûnglobulîna G (Ig G) CMV lîmenis asinîs. Pozitîvas IgG antivielas pret CMV tika atrastas 95 pacientiem no 102 (92,2%) slimnieku
grupâ un 45 no 48 kontrolgrupas dalîbniekiem. Rezultâti starp grupâm statistiski ticami neatðíîrâs (χ2 = 0.02; P > 0,05). Vidçjais CMV
antivielu lîmenis asins serumâ pacientu grupâ bija nedaudz augstâks nekâ kontrolgrupai, bet rezultâti statistiski ticami neatðíîrâs (t = 1,274;
P > 0,05). Analizçjot pozitîvas antivielas pret CMV statistiski ticama korelâcija bija atrasta ar iekaisuma radîtâju – leikocitozi (r = 0,282;
P < 0,01), pozitîvâm antivielâm pret CMV un KSS (r = 0,239; P < 0,05), pozitîvâm antivielâm pret CMV un intîma-media kompleksa
biezumu (r = 0,221; P < 0,05). Korelâcija ar citiem insulta riska faktoriem netika atrasta.
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